We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

82 hedge funds and large institutions have $146M invested in Akebia Therapeutics in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 16

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

12% more funds holding

Funds holding: 73 → 82 (+9)

7% more capital invested

Capital invested by funds: $136M → $146M (+$9.98M)

14% less call options, than puts

Call options by funds: $1.23M | Put options by funds: $1.43M

Holders
82
Holders Change
+9
Holders Change %
+12.33%
% of All Funds
2.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
32
Reduced
16
Closed
11
Calls
$1.23M
Puts
$1.43M
Net Calls
-$206K
Net Calls Change
-$310K

Top Buyers

Rank Fund Capital Flow
1
EAM
Eagle Asset Management
Florida
+$7.65M
2
VAM
Visium Asset Management
New York
+$5.1M
3
BIT
BlackRock Institutional Trust
California
+$3.49M
4
PA
Perceptive Advisors
New York
+$2.39M
5
EI
EAM Investors
California
+$2.22M

Top Sellers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$8.52M
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.48M
3
BIM
Bogle Investment Management
Massachusetts
-$1.97M
4
Deutsche Bank
Deutsche Bank
Germany
-$1.42M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$623K
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
1
Eagle Asset Management
Florida
$31.6M +$7.65M +834,064 +34%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$19M – – –
NHAS
3
Novo Holdings A/S
Denmark
$14.6M – – –
BFA
4
BlackRock Fund Advisors
California
$9.86M +$290K +31,621 +3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.93M +$1.1M +120,208 +24%
VAM
6
Visium Asset Management
New York
$5.37M +$5.1M +556,000 New
BIT
7
BlackRock Institutional Trust
California
$5.28M +$3.49M +380,520 +230%
Stifel Financial
8
Stifel Financial
Missouri
$4.3M +$3.63K +396 +0.1%
Marshall Wace
9
Marshall Wace
United Kingdom
$4.13M +$257K +28,032 +7%
Bank of America
10
Bank of America
North Carolina
$3.17M +$2.09M +227,318 +224%
State Street
11
State Street
Massachusetts
$2.68M +$422K +46,028 +20%
PA
12
Perceptive Advisors
New York
$2.51M +$2.39M +260,000 New
EMFAT
13
Emerald Mutual Fund Advisers Trust
Pennsylvania
$2.48M -$459K -50,000 -16%
EI
14
EAM Investors
California
$2.33M +$2.22M +241,440 New
Northern Trust
15
Northern Trust
Illinois
$2.25M +$932K +101,602 +77%
Millennium Management
16
Millennium Management
New York
$2.05M +$1.7M +185,586 +700%
Ameriprise
17
Ameriprise
Minnesota
$1.67M +$1.59M +173,334 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$1.41M +$685K +74,596 +104%
First Manhattan
19
First Manhattan
New York
$1.27M +$1.2M +131,304 New
PAWC
20
P.A.W. Capital
Connecticut
$1.26M +$1.19M +130,000 New
PAM
21
Panagora Asset Management
Massachusetts
$1.25M +$229K +24,987 +24%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$1.23M +$54.4K +5,932 +5%
Morgan Stanley
23
Morgan Stanley
New York
$1.09M +$594K +64,722 +134%
Renaissance Technologies
24
Renaissance Technologies
New York
$1.07M -$2.48M -270,539 -71%
CAM
25
Cormorant Asset Management
Massachusetts
$969K – – –
1
2 3 4

AKBA Hedge Fund Activity: Q3 2015 in Review

82 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2015, worth a combined $146M — up 7.4% from $136M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AKBA positions and 11 closed out — a net gain of 9 holders — while 32 added to existing stakes and 16 trimmed.

The largest buyer was Eagle Asset Management, adding an estimated $7.65M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $8.52M sold.

  • 82 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2015, up from 73 in Q2 2015.
  • Funds reported $146M of Akebia Therapeutics stock for Q3 2015, up 7.4% quarter-over-quarter.
  • 20 funds opened new Akebia Therapeutics positions in Q3 2015 and 11 closed out, a net change of +9 holders.
  • The largest Akebia Therapeutics buyer in Q3 2015 was Eagle Asset Management, an estimated $7.65M added.
  • The largest Akebia Therapeutics seller in Q3 2015 was Balyasny Asset Management, an estimated $8.52M sold.

Based on aggregated 13F filings for Q3 2015.